• Multi-national study testing ability of NOX66 to enhance radiotherapy
• First cohort of patients treated
• Direct and abscopal responses being evaluated
Sydney, 5 April 2018: Noxopharm (ASX:NOX) today announces that the first cohort of 4 patients has commenced treatment in the Company’s key DARRT-1 clinical study.
The DARRT-1 study is being conducted at 11 centres in Australia, New Zealand and Georgia. It involves men with late-stage prostate cancer (metastatic, castrate-resistant disease) receiving NOX66 in combination with a palliative (low) dose of radiotherapy. The first four patients have been recruited in Australia (1) and Georgia (3).
For further information please download PDF attached:
Download this document
